PMC:7029759 / 9636-11523
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
220 | 31-40 | Species | denotes | 2019-nCoV | Tax:2697049 |
221 | 6-22 | Chemical | denotes | oligonucleotides | MESH:D009841 |
236 | 93-102 | Species | denotes | 2019-nCoV | Tax:2697049 |
237 | 193-202 | Species | denotes | 2019-nCoV | Tax:2697049 |
238 | 522-530 | Species | denotes | CoV-2019 | Tax:2697049 |
239 | 721-730 | Species | denotes | 2019-nCoV | Tax:2697049 |
240 | 738-748 | Species | denotes | SARS virus | Tax:694009 |
241 | 1477-1482 | Species | denotes | Ebola | Tax:1570291 |
242 | 354-370 | Chemical | denotes | oligonucleotides | MESH:D009841 |
243 | 658-673 | Chemical | denotes | oligonucleotide | MESH:D009841 |
244 | 853-869 | Chemical | denotes | oligonucleotides | MESH:D009841 |
245 | 960-965 | Chemical | denotes | lipid | MESH:D008055 |
246 | 1141-1150 | Disease | denotes | infection | MESH:D007239 |
247 | 1396-1411 | Disease | denotes | viral infection | MESH:D001102 |
248 | 1713-1721 | Disease | denotes | infected | MESH:D007239 |
249 | 236-246 | CellLine | denotes | MN908947.3 | CVCL:U508 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T184 | 31-40 | SP_7 | denotes | 2019-nCoV |
T183 | 45-51 | SO:0001026 | denotes | genome |
T182 | 73-80 | GO:0009986 | denotes | surface |
T181 | 93-102 | SP_7 | denotes | 2019-nCoV |
T180 | 134-140 | SO:0001026 | denotes | genome |
T179 | 174-180 | SO:0001026 | denotes | genome |
T178 | 193-202 | SP_7 | denotes | 2019-nCoV |
T177 | 311-332 | SO:0000646 | denotes | small interfering RNA |
T176 | 334-339 | SO:0000646 | denotes | siRNA |
T175 | 344-353 | SO:0000077 | denotes | antisense |
T174 | 391-396 | NCBITaxon:10239 | denotes | virus |
T173 | 418-424 | SO:0001026 | denotes | genome |
T172 | 511-518 | SO:0000417 | denotes | domains |
T171 | 612-617 | SO:0000646 | denotes | siRNA |
T170 | 638-643 | NCBITaxon:10239 | denotes | viral |
T169 | 702-708 | SO:0001026 | denotes | genome |
T168 | 709-717 | SO:0000853 | denotes | homology |
T167 | 721-730 | SP_7 | denotes | 2019-nCoV |
T166 | 738-748 | NCBITaxon:10633 | denotes | SARS virus |
T165 | 898-903 | UBERON:0000170 | denotes | lungs |
T164 | 960-965 | CHEBI:18059;CHEBI:18059 | denotes | lipid |
T163 | 1020-1025 | UBERON:0000170 | denotes | lungs |
T162 | 1064-1069 | SO:0000646 | denotes | siRNA |
T161 | 1123-1128 | UBERON:0000170 | denotes | lungs |
T160 | 1219-1227 | UBERON:0004821;CL:0000322 | denotes | alveolar |
T159 | 1228-1238 | CL:0000322;UBERON:0004821 | denotes | epithelial |
T158 | 1239-1244 | CL:0000322 | denotes | cells |
T157 | 1252-1256 | UBERON:0002048 | denotes | lung |
T156 | 1261-1266 | SO:0000646 | denotes | siRNA |
T155 | 1340-1344 | SO:0000704 | denotes | gene |
T154 | 1396-1401 | NCBITaxon:10239 | denotes | viral |
T153 | 1452-1457 | SO:0000646 | denotes | siRNA |
T152 | 1547-1553 | NCBITaxon:33208 | denotes | animal |
T151 | 1602-1607 | SO:0000646 | denotes | siRNA |
T150 | 1690-1695 | SO:0000646 | denotes | siRNA |
T149 | 1696-1701 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
T148 | 1742-1747 | SO:0000646 | denotes | siRNA |
T147 | 1867-1878 | CHEBI:23888;CHEBI:23888 | denotes | medications |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T39 | 41-44 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T40 | 45-51 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T41 | 81-89 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T42 | 130-133 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T43 | 134-140 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T44 | 170-173 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T45 | 174-180 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T46 | 329-332 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T47 | 414-417 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T48 | 418-424 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T49 | 498-501 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T50 | 702-708 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T51 | 898-903 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T52 | 960-965 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
T53 | 1020-1025 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T54 | 1123-1128 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T55 | 1219-1244 | Body_part | denotes | alveolar epithelial cells | http://purl.org/sig/ont/fma/fma62499 |
T56 | 1239-1244 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T57 | 1252-1256 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T58 | 1340-1344 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T4 | 1252-1256 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T5 | 1664-1669 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T25 | 738-742 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T26 | 1141-1150 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T27 | 1396-1411 | Disease | denotes | viral infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
T28 | 1402-1411 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T29 | 1477-1482 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T86 | 391-396 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T87 | 743-748 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T88 | 823-824 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T89 | 898-903 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T90 | 1020-1025 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T91 | 1123-1128 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T92 | 1159-1160 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T93 | 1228-1256 | http://purl.obolibrary.org/obo/CL_0000082 | denotes | epithelial cells in the lung |
T94 | 1308-1309 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T95 | 1340-1344 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T96 | 1394-1395 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T97 | 1547-1553 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T98 | 1565-1567 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T99 | 1643-1644 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T100 | 1705-1706 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T23 | 6-22 | Chemical | denotes | oligonucleotides | http://purl.obolibrary.org/obo/CHEBI_7754 |
T24 | 81-89 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T25 | 354-370 | Chemical | denotes | oligonucleotides | http://purl.obolibrary.org/obo/CHEBI_7754 |
T26 | 658-673 | Chemical | denotes | oligonucleotide | http://purl.obolibrary.org/obo/CHEBI_7754 |
T27 | 853-869 | Chemical | denotes | oligonucleotides | http://purl.obolibrary.org/obo/CHEBI_7754 |
T28 | 960-965 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
T29 | 966-979 | Chemical | denotes | nanoparticles | http://purl.obolibrary.org/obo/CHEBI_50803 |
T30 | 1696-1701 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 152-163 | http://purl.obolibrary.org/obo/GO_0009056 | denotes | degradation |
T5 | 1396-1411 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infection |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T58 | 0-51 | Sentence | denotes | Using oligonucleotides against 2019-nCoV RNA genome |
T59 | 52-164 | Sentence | denotes | Beyond targeting the surface proteins of 2019-nCoV, one could also target the RNA genome itself for degradation. |
T60 | 165-428 | Sentence | denotes | This RNA genome sequence of 2019-nCoV was recently published (GenBank: MN908947.3), and one strategy that could be considered then, is the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASO) to combat the virus by targeting its RNA genome 23. |
T61 | 429-476 | Sentence | denotes | The challenge with this strategy is multi-fold. |
T62 | 477-545 | Sentence | denotes | First, the conserved RNA sequence domains of CoV-2019 are not known. |
T63 | 546-683 | Sentence | denotes | Identifying conserved sequences is essential in order to optimize siRNA targeting and avoid viral escape of the oligonucleotide strategy. |
T64 | 684-822 | Sentence | denotes | One could look at genome homology of 2019-nCoV to the SARS virus for comparison of conserved sequences, but this would still be guesswork. |
T65 | 823-904 | Sentence | denotes | A second challenge is how the oligonucleotides would be delivered into the lungs. |
T66 | 905-1029 | Sentence | denotes | Advances have been made into delivery vehicles such as lipid nanoparticles that can mediate some delivery into the lungs 24. |
T67 | 1030-1195 | Sentence | denotes | It is unknown, however, if enough siRNA’s or ASO’s would be effectively delivered within the lungs to stop the infection or make a difference in its clinical course. |
T68 | 1196-1412 | Sentence | denotes | For example, if 25% of alveolar epithelial cells in the lung had siRNA or ASO in them, that efficiency might be a great success for traditional gene therapy, but would hardly make any difference in a viral infection. |
T69 | 1413-1568 | Sentence | denotes | Such an explanation is also likely why siRNA candidates against Ebola failed in trials 25, despite significant success in preclinical animal models 26, 27. |
T70 | 1569-1733 | Sentence | denotes | Lastly, even if one assumed that siRNA was effective clinically, there is a limited ability to scale up manufacturing of siRNA drugs to a large infected population. |
T71 | 1734-1887 | Sentence | denotes | Current siRNA and ASO therapies are manufactured for rare diseases, and there are no available resources existing to manufacture the medications quickly. |